{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:34:22Z","timestamp":1780626862474,"version":"3.54.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T00:00:00Z","timestamp":1368662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40265-013-0063-x","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T13:41:07Z","timestamp":1368625267000},"page":"825-843","source":"Crossref","is-referenced-by-count":15,"title":["Apixaban: A Review of its Use for Reducing the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation"],"prefix":"10.1007","volume":"73","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,16]]},"reference":[{"issue":"21","key":"63_CR1","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","volume":"33","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719\u201347.","journal-title":"Eur Heart J"},{"issue":"4","key":"63_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/11592410-000000000-00000","volume":"11","author":"P Deedwania","year":"2011","unstructured":"Deedwania P, Huang GW. Role of emerging antithrombotic therapy in prevention of cardioembolic complications in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2011;11(4):265\u201375.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"12","key":"63_CR3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857\u201367.","journal-title":"Ann Intern Med"},{"issue":"9","key":"63_CR4","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2165\/11209020-000000000-00000","volume":"72","author":"ED Deeks","year":"2012","unstructured":"Deeks ED. Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Drugs. 2012;72(9):1271\u201391.","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"63_CR5","first-page":"640","volume":"32","author":"G Lu","year":"2011","unstructured":"Lu G, Deguzman FR, Karbarz MJ, et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445) [abstract no. 3715]. Eur Heart J. 2011;32(Suppl. 1):640\u20131.","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"63_CR6","first-page":"133","volume":"29","author":"P Wong","year":"2008","unstructured":"Wong P, Watson C, Knabb R, et al. The combination of apixaban, a direct Xa inhibitor, with heparin or enoxaparin in rabbits elicits additive antithrombotic effects, with low bleeding [abstract no. 933]. Eur Heart J. 2008;29(Suppl. 1):133\u20134.","journal-title":"Eur Heart J"},{"issue":"13 Suppl.","key":"63_CR7","doi-asserted-by":"crossref","first-page":"E1697","DOI":"10.1016\/S0735-1097(12)61698-2","volume":"59","author":"JH Alexander","year":"2012","unstructured":"Alexander JH, Lopes R, McMurray J, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in patients taking concomitant aspirin [abstract no. 1192\u2013600]. J Am Coll Cardiol. 2012;59(13 Suppl.):E1697.","journal-title":"J Am Coll Cardiol"},{"key":"63_CR8","doi-asserted-by":"crossref","unstructured":"Hollenbach SJ, Lu G, Tan S, et al. PRT064445 but not recombinant FVIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model [abstract no. 3414]. 54th American Society of Haematology annual meeting and exposition; 8\u201311 Dec 2012; Atlanta (GA).","DOI":"10.1182\/blood.V120.21.3414.3414"},{"issue":"5","key":"63_CR9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1160\/TH10-05-0328","volume":"104","author":"YC Barrett","year":"2010","unstructured":"Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(5):1263\u201371.","journal-title":"Thromb Haemost"},{"issue":"22","key":"63_CR10","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"DJ Pinto","year":"2007","unstructured":"Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50(22):5339\u201356.","journal-title":"J Med Chem"},{"issue":"4","key":"63_CR11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","volume":"31","author":"PC Wong","year":"2011","unstructured":"Wong PC, Pinto DJP, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478\u201392.","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"63_CR12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14756366.2010.535793","volume":"26","author":"JM Luettgen","year":"2011","unstructured":"Luettgen JM, Knabb RM, He K, et al. Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem. 2011;26(4):514\u201326.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"63_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","volume":"48","author":"BI Eriksson","year":"2009","unstructured":"Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"63_CR14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1160\/TH08-07-0486","volume":"101","author":"X Jiang","year":"2009","unstructured":"Jiang X, Crain EJ, Luettgen JM, et al. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost. 2009;101(4):780\u20132.","journal-title":"Thromb Haemost"},{"issue":"5","key":"63_CR15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","volume":"6","author":"PC Wong","year":"2008","unstructured":"Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820\u20139.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"63_CR16","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1160\/TH10-04-0247","volume":"104","author":"RC Becker","year":"2010","unstructured":"Becker RC, Alexander JH, Newby LK, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010;104(5):976\u201383.","journal-title":"Thromb Haemost"},{"issue":"8","key":"63_CR17","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","volume":"75","author":"S Ogawa","year":"2011","unstructured":"Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation: the ARISTOTLE-J study. Circ J. 2011;75(8):1852\u20139.","journal-title":"Circ J"},{"key":"63_CR18","unstructured":"Bristol-Myers Squibb Company. Eliquis (apixaban) tablets for oral use: US prescribing information; 2012. http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf (Accessed 30 Jan 2013)."},{"issue":"2","key":"63_CR19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","volume":"75","author":"C Frost","year":"2013","unstructured":"Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476\u201387.","journal-title":"Br J Clin Pharmacol"},{"key":"63_CR20","doi-asserted-by":"crossref","unstructured":"Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013. doi: 10.1111\/bcp.12106 .","DOI":"10.1111\/bcp.12106"},{"key":"63_CR21","unstructured":"European Medicines Agency. Eliquis (apixaban) film-coated tablets: EU summary of product characteristics; 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf (Accessed 30 Jan 2013)."},{"issue":"1","key":"63_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1160\/TH10-06-0393","volume":"105","author":"YC Barrett","year":"2011","unstructured":"Barrett YC, Wang J, Knabb R, et al. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost. 2011;105(1):181\u20139.","journal-title":"Thromb Haemost"},{"issue":"2","key":"63_CR23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1160\/TH10-02-0097","volume":"104","author":"PC Wong","year":"2010","unstructured":"Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost. 2010;104(2):302\u201310.","journal-title":"Thromb Haemost"},{"issue":"6","key":"63_CR24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/FJC.0b013e3181daded3","volume":"55","author":"WA Schumacher","year":"2010","unstructured":"Schumacher WA, Bostwick JS, Stewart AB, et al. Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. J Cardiovasc Pharmacol. 2010;55(6):609\u201316.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"63_CR25","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2009.03503.x","volume":"7","author":"PC Wong","year":"2009","unstructured":"Wong PC, Crain EJ, Watson CA, et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost. 2009;7(8):1313\u201320.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"63_CR26","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/j.1538-7836.2008.03092.x","volume":"6","author":"PC Wong","year":"2008","unstructured":"Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost. 2008;6(10):1736\u201341.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"63_CR27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"63_CR28","first-page":"S34","volume":"85","author":"CE Frost","year":"2009","unstructured":"Frost CE, Yu Z, Wang J, et al. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment [abstract no. PI-84]. Clin Pharmacol Ther. 2009;85(Suppl. 1):S34.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 1","key":"63_CR29","first-page":"S41","volume":"91","author":"X Wang","year":"2012","unstructured":"Wang X, Tirucherai G, Pannacciulli N, et al. Effect of activated charcoal on the pharmacokinetics of apixaban in healthy subjects [abstract no. PI-90]. Clin Pharmacol Ther. 2012;91(Suppl. 1):S41.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 2","key":"63_CR30","first-page":"455","volume":"7","author":"CE Frost","year":"2009","unstructured":"Frost CE, Nepal S, Barrett Y. Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban [abstract no. PP-MO-407]. J Thromb Haemost. 2009;7(Suppl. 2):455.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"63_CR31","first-page":"187","volume":"1","author":"X Wang","year":"2012","unstructured":"Wang X, Tirucherai G, Ehlgen A, et al. Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis [abstract no. 1391147]. Clin Pharmacol Drug Dev. 2012;1(4):187.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"63_CR32","first-page":"185","volume":"1","author":"M Chang","year":"2012","unstructured":"Chang M, Shenker A, Wang J, et al. Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment [abstract no. 1381212]. Clin Pharmacol Drug Dev. 2012;1(4):185\u20136.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"63_CR33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","volume":"38","author":"L Wang","year":"2010","unstructured":"Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448\u201358.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"63_CR34","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1124\/dmd.108.025981","volume":"37","author":"D Zhang","year":"2009","unstructured":"Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009;37(8):1738\u201348.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"63_CR35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","volume":"37","author":"N Raghavan","year":"2009","unstructured":"Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74\u201381.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"63_CR36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/dmd.112.050260","volume":"41","author":"D Zhang","year":"2013","unstructured":"Zhang D, He K, Herbst JJ, et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41(4):827\u201335.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"63_CR37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/dmd.112.050575","volume":"41","author":"D Zhang","year":"2013","unstructured":"Zhang D, Frost CE, He K, et al. Investigating the enteroenteric recirculation of apixaban, a factor xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos. 2013;41(4):906\u201315.","journal-title":"Drug Metab Dispos"},{"key":"63_CR38","doi-asserted-by":"crossref","unstructured":"Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013. doi: 10.1111\/bcp.12114 .","DOI":"10.1111\/bcp.12114"},{"issue":"11","key":"63_CR39","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"9","key":"63_CR40","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806\u201317.","journal-title":"N Engl J Med"},{"key":"63_CR41","doi-asserted-by":"crossref","unstructured":"Wallentin L, Lopes RD, Hanna M, et al. ARISTOTLE: efficacy and safety of apixaban compared to warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trial [abstract plus slide presentation]. European Society of Cardiology Congress 2011; 27\u201331 Aug 2011; Paris.","DOI":"10.1016\/j.cjca.2011.07.611"},{"key":"63_CR42","first-page":"685","volume":"33 Suppl","author":"CB Granger","year":"2012","unstructured":"Granger CB, Alexander JH, Hanna M, et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial [abstract no. 4045]. Eur Heart J. 2012;33 Suppl:685\u20136.","journal-title":"Eur Heart J"},{"key":"63_CR43","unstructured":"Garcia DA, Alexander JH, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation in relation to prior warfarin use: insights from the ARISTOTLE trial [abstract no. 14771]. Circulation. 2012;126(21 Suppl.)."},{"key":"63_CR44","unstructured":"Bahit MC, Lopes RD, Hohnloser S, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial [abstract no. 13026]. Circulation. 2012;126(21 Suppl.)."},{"issue":"Suppl. 1","key":"63_CR45","first-page":"51","volume":"33","author":"LC Wallentin","year":"2012","unstructured":"Wallentin LC, Christersson C, Siegbahn A, et al. NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin [abstract no. P551]. Eur Heart J. 2012;33(Suppl. 1):51.","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"63_CR46","first-page":"53","volume":"33","author":"LC Wallentin","year":"2012","unstructured":"Wallentin LC, Christersson C, Siegbahn A, et al. High sensitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin [abstract no. P558]. Eur Heart J. 2012;33(Suppl. 1):53.","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"63_CR47","first-page":"686","volume":"33","author":"G Flaker","year":"2012","unstructured":"Flaker G, Lopes R, Al-Khatib S, et al. Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE Trial [abstract no. 4048]. Eur Heart J. 2012;33(Suppl. 1):686.","journal-title":"Eur Heart J"},{"key":"63_CR48","doi-asserted-by":"crossref","unstructured":"Halvorsen S, Wallentin L, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation [abstract no. 914-4]. J Am Coll Cardiol. 2013;61(10 Suppl.):E315 plus slide presentation presented at the 62nd Annual Scientific Session and Exposition of the American College of Cardiology; 9\u201311 Mar 2013; San Francisco (CA).","DOI":"10.1016\/S0735-1097(13)60315-0"},{"key":"63_CR49","doi-asserted-by":"crossref","unstructured":"Flaker GC, Hohnloser S, Wojdyla D, et al. Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: an analysis from the ARISTOTLE trial [abstract no. 914-6]. J Am Coll Cardiol. 2013;61(10 Suppl.):E317 plus slide presentation presented at the 62nd Annual Scientific Session and Exposition of the American College of Cardiology; 9\u201311 Mar 2013; San Francisco (CA).","DOI":"10.1016\/S0735-1097(13)60317-4"},{"key":"63_CR50","unstructured":"McMurray JJV. Apixaban vs warfarin in patients with atrial fibrillation: outcomes according to left ventricular systolic function and heart failure status in ARISTOTLE [slide presentation]. European Society of Cardiology Heart Failure Congress 2012; 19\u201322 May 2012; Belgrade."},{"issue":"6","key":"63_CR51","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","volume":"11","author":"JD Easton","year":"2012","unstructured":"Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503\u201311.","journal-title":"Lancet Neurol"},{"issue":"22","key":"63_CR52","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","volume":"33","author":"SH Hohnloser","year":"2012","unstructured":"Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821\u201330.","journal-title":"Eur Heart J"},{"issue":"9855","key":"63_CR53","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","volume":"380","author":"RD Lopes","year":"2012","unstructured":"Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380(9855):1749\u201358.","journal-title":"Lancet"},{"key":"63_CR54","doi-asserted-by":"crossref","unstructured":"Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013. doi: 10.1093\/eurheartj\/eht135 .","DOI":"10.1093\/eurheartj\/eht135"},{"issue":"Suppl. 1","key":"63_CR55","first-page":"671","volume":"32","author":"S Hohnloser","year":"2011","unstructured":"Hohnloser S, Yusuf S, Eikelboom J, et al. Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial [abstract no. 3904]. Eur Heart J. 2011;32(Suppl. 1):671.","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"63_CR56","first-page":"465","volume":"32","author":"J Eikelboom","year":"2011","unstructured":"Eikelboom J, Synhorst D, Wright R, et al. Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: a secondary analysis of the AVERROES trial [abstract no. P2631]. Eur Heart J. 2011;32(Suppl. 1):465.","journal-title":"Eur Heart J"},{"issue":"3","key":"63_CR57","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","volume":"11","author":"H-C Diener","year":"2012","unstructured":"Diener H-C, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11(3):225\u201331.","journal-title":"Lancet Neurol"},{"issue":"6","key":"63_CR58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.05.007","volume":"21","author":"JW Eikelboom","year":"2012","unstructured":"Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21(6):429\u201335.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"63_CR59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCEP.112.975847","volume":"6","author":"GYH Lip","year":"2013","unstructured":"Lip GYH, Connolly S, Yusuf S, et al. Modification of outcomes with aspirin or apixaban in relation to CHADS2 and CHA2DS2-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Circ Arrhythm Electrophysiol. 2013;6(1):31\u20138.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"Suppl. 1","key":"63_CR60","first-page":"51","volume":"33","author":"A Siegbahn","year":"2012","unstructured":"Siegbahn A, Christersson C, Schollin M, et al. Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding: an ARISTOTLE substudy [abstract no. P553]. Eur Heart J. 2012;33(Suppl. 1):51.","journal-title":"Eur Heart J"},{"issue":"12","key":"63_CR61","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1161\/STROKEAHA.112.664144","volume":"43","author":"GC Flaker","year":"2012","unstructured":"Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial. Stroke. 2012;43(12):3291\u20137.","journal-title":"Stroke"},{"issue":"10","key":"63_CR62","doi-asserted-by":"crossref","first-page":"e47473","DOI":"10.1371\/journal.pone.0047473","volume":"7","author":"S Lee","year":"2012","unstructured":"Lee S, Mullin R, Blazawski J, et al. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS ONE. 2012;7(10):e47473.","journal-title":"PLoS ONE"},{"issue":"14","key":"63_CR63","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1212\/WNL.0b013e31826d5fe8","volume":"79","author":"H Kamel","year":"2012","unstructured":"Kamel H, Easton JD, Johnston SC, et al. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology. 2012;79(14):1428\u201334.","journal-title":"Neurology"},{"issue":"4","key":"63_CR64","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/CIRCOUTCOMES.112.965251","volume":"5","author":"S Lee","year":"2012","unstructured":"Lee S, Anglade MW, Meng J, et al. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes. 2012;5(4):472\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"63_CR65","doi-asserted-by":"crossref","unstructured":"Cowper PA, Pan W, Anstrom K, et al. Apixaban reduces hospitalization in patients with atrial fibrillation: an analysis of the effect of apixaban therapy on resource use in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial [abstract no. 1245-108]. J Am Coll Cardiol. 2013;61(10 Suppl.):E1576 plus poster presented at the 62nd Annual Scientific Session and Exposition of the American College of Cardiology; 9\u201311 Mar 2013; San Francisco (CA).","DOI":"10.1016\/S0735-1097(13)61576-4"},{"issue":"7","key":"63_CR66","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","volume":"123","author":"IM Ogilvie","year":"2010","unstructured":"Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638\u201345.","journal-title":"Am J Med"},{"issue":"6","key":"63_CR67","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","volume":"107","author":"JB Olesen","year":"2012","unstructured":"Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0\u20131: a nationwide cohort study. Thromb Haemost. 2012;107(6):1172\u20139.","journal-title":"Thromb Haemost"},{"issue":"9855","key":"63_CR68","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(12)61673-0","volume":"380","author":"VS Vassiliou","year":"2012","unstructured":"Vassiliou VS, Flynn PD. Apixaban in atrial fibrillation: does predicted risk matter? Lancet. 2012;380(9855):1718\u201320.","journal-title":"Lancet"},{"issue":"8","key":"63_CR69","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/STROKEAHA.111.619338","volume":"42","author":"BL Cucchiara","year":"2011","unstructured":"Cucchiara BL, Kasner SE. Apixaban in atrial fibrillation: from bleeding cows to 21st century medicinal chemistry. Stroke. 2011;42(8):2376\u20138.","journal-title":"Stroke"},{"issue":"3","key":"63_CR70","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/STROKEAHA.111.640961","volume":"43","author":"K Nedeltchev","year":"2012","unstructured":"Nedeltchev K. Critique of apixaban versus warfarin in patients with atrial fibrillation. Stroke. 2012;43(3):922\u20133.","journal-title":"Stroke"},{"issue":"4","key":"63_CR71","first-page":"521","volume":"126","author":"G Escolar","year":"2012","unstructured":"Escolar G, Arellano-Rodrigo E, Reverter CJ, et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood [abstract]. Circulation. 2012;126(4):521.","journal-title":"Circulation"},{"key":"63_CR72","unstructured":"Portola Pharmaceuticals. Phase 2 healthy volunteer study to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests [ClinicalTrials.gov identifier NCT01758432]. US National Institutes of Health, ClinicalTrials.gov [online]; 2012. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01758432 (Accessed 29 Jan 2013)."},{"issue":"10","key":"63_CR73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"12","key":"63_CR74","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"key":"63_CR75","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa\u00ae (dabigatran etexilate mesylate) capsules: US prescribing information; 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022512s016lbl.pdf (Accessed 7 Feb 2013)."},{"issue":"22","key":"63_CR76","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1093\/eurheartj\/ehs267","volume":"33","author":"J Steffel","year":"2012","unstructured":"Steffel J, Hindricks G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. Eur Heart J. 2012;33(22):2766\u20138.","journal-title":"Eur Heart J"},{"issue":"21","key":"63_CR77","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"123","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363\u201372.","journal-title":"Circulation"},{"issue":"9","key":"63_CR78","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","volume":"366","author":"P Harper","year":"2012","unstructured":"Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864\u20136.","journal-title":"N Engl J Med"},{"key":"63_CR79","unstructured":"European Medicines Agency. Pradaxa (dabigatran) hard capsules: EU summary of product characteristics; 2013. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf (Accessed 12 Feb 2013)."},{"key":"63_CR80","unstructured":"European Medicines Agency. Xarelto (rivaoxaban) film-coated tablets: EU summary of product characteristics; 2013. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf (Accessed 12 Feb 2013)."},{"key":"63_CR81","unstructured":"Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) tablets: US prescribing information; 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022406s001s002s003lbl.pdf (Accessed 7 Feb 2013)."},{"issue":"11","key":"63_CR82","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJMe1109748","volume":"365","author":"JL Mega","year":"2011","unstructured":"Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365(11):1052\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"63_CR83","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","volume":"108","author":"S Mantha","year":"2012","unstructured":"Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108(3):476\u201384.","journal-title":"Thromb Haemost"},{"issue":"8","key":"63_CR84","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","volume":"60","author":"GY Lip","year":"2012","unstructured":"Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60(8):738\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"63_CR85","first-page":"815","volume":"33","author":"S Marx","year":"2012","unstructured":"Marx S, Diener HC, Harenberg J, et al. Network meta-analysis of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation [abstract no. P4695]. Eur Heart J. 2012;33(Suppl. 1):815.","journal-title":"Eur Heart J"},{"key":"63_CR86","doi-asserted-by":"crossref","first-page":"e7097","DOI":"10.1136\/bmj.e7097","volume":"345","author":"LH Rasmussen","year":"2012","unstructured":"Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012;345:e7097.","journal-title":"BMJ"},{"issue":"2","key":"63_CR87","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1160\/TH12-08-0539","volume":"109","author":"R Pisters","year":"2013","unstructured":"Pisters R, Nieuwlaat R, Lane DA, et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation: a modelling analysis from the Euro Heart Survey. Thromb Haemost. 2013;109(2):328\u201336.","journal-title":"Thromb Haemost"},{"issue":"3","key":"63_CR88","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","volume":"107","author":"A Banerjee","year":"2012","unstructured":"Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584\u20139.","journal-title":"Thromb Haemost"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0063-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0063-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0063-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T19:41:04Z","timestamp":1595792464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0063-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,16]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0063-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,16]]}}}